Clinical Trials Browser

Phase 1/2 × Advanced Non-small Cell Lung Cancer × 30 days × Clear all

NCT05099172 2026-03-12

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 1/2 Active not recruiting

370 enrolled 1 FDA

Advanced Non-small Cell Lung Cancer